Nkx-3.1 Antibody (820C3a): sc-81340
- Nkx-3.1 Antibody (820C3a) is a mouse monoclonal IgG1, cited in 1 publications, provided at 100 µg/ml
- raised against a recombinant protein corresponding to an internal region of Nkx-3.1 of human origin
- recommended for detection of Nkx-3.1 of human origin by WB and IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Nkx-3.1 Antibody (820C3a). This work is in progress.
Nkx-3.1 Antibody (820C3a) is a mouse monoclonal IgG1 antibody that detects Nkx-3.1 in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Nkx-3.1 is a crucial homeobox gene that plays a significant role in prostate development, primarily responding to sonic hedgehog (Shh) signaling, which is essential for regulating the growth and differentiation of prostatic epithelium. Nkx-3.1 is predominantly expressed in the prostate but is also found at lower levels in other tissues, including the heart and gut, where Nkx-3.1 contributes to the regulation of glandular epithelium proliferation and duct formation in both the prostate and minor salivary glands. The unique binding affinity of Nkx-3.1 for the TAAGTA sequence distinguishes Nkx-3.1 from other NK class homeoproteins, highlighting its specialized function in gene regulation. Located on chromosome 8q21, the Nkx-3.1 gene is subject to loss of heterozygosity, making Nkx-3.1 a potential marker for assessing benign and malignant conditions in prostate epithelium, despite not being classified as a tumor suppressor gene. Anti-Nkx-3.1 antibody (820C3a) is an invaluable tool for researchers investigating the molecular mechanisms underlying prostate biology and related pathologies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Nkx-3.1 Antibody (820C3a) References:
- NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. | Chen, H., et al. 2002. Cancer Res. 62: 338-40. PMID: 11809674
- NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. | Muhlbradt, E., et al. 2009. Cancer Res. 69: 2615-22. PMID: 19258508
- NKX3.1 potentiates TNF-alpha/CHX-induced apoptosis of prostate cancer cells through increasing caspase-3 expression and its activity. | Pengju, Z., et al. 2010. Biochem Biophys Res Commun. 398: 457-61. PMID: 20599703
- NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. | Locke, JA., et al. 2012. Clin Cancer Res. 18: 308-16. PMID: 22048240
- Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants. | Padmanabhan, A., et al. 2016. Prostate. 76: 523-33. PMID: 26841725
- Loss of glutathione peroxidase 3 induces ROS and contributes to prostatic hyperplasia in Nkx3.1 knockout mice. | Kim, U., et al. 2020. Andrology. 8: 1486-1493. PMID: 32450005
- NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. | Papachristodoulou, A., et al. 2021. Cancer Discov. 11: 2316-2333. PMID: 33893149
- LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer. | Sooreshjani, MA., et al. 2021. Cancers (Basel). 13: PMID: 34066036
- Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. | Papachristodoulou, A., et al. 2024. Eur Urol. 85: 361-372. PMID: 37659962
- NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma. | Mehreen, A., et al. 2024. Adv Anat Pathol. 31: 202-205. PMID: 38525603
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nkx-3.1 Antibody (820C3a) | sc-81340 | 100 µg/ml | $333.00 |